首页> 外文期刊>biomolecules >Utility of the Specialized Pro-Resolving Mediators as Diagnostic and Prognostic Biomarkers in Disease
【24h】

Utility of the Specialized Pro-Resolving Mediators as Diagnostic and Prognostic Biomarkers in Disease

机译:专门的促解介质作为疾病诊断和预后生物标志物的效用

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

A precision medicine approach is widely acknowledged to yield more effective therapeutic strategies in the treatment of patients with chronic inflammatory conditions than the prescriptive paradigm currently utilized in the management and treatment of these patients. This is because such an approach will take into consideration relevant factors including the likelihood that a patient will respond to given therapeutics based on their disease phenotype. Unfortunately, the application of this precision medicine paradigm in the daily treatment of patients has been greatly hampered by the lack of robust biomarkers, in particular biomarkers for determining early treatment responsiveness. Lipid mediators are central in the regulation of host immune responses during both the initiation and resolution of inflammation. Amongst lipid mediators, the specialized pro-resolving mediators (SPM) govern immune cells to promote the resolution of inflammation. These autacoids are produced via the stereoselective conversion of essential fatty acids to yield molecules that are dynamically regulated during inflammation and exert potent immunoregulatory activities. Furthermore, there is an increasing appreciation for the role that these mediators play in conveying the biological actions of several anti-inflammatory therapeutics, including statins and aspirin. Identification and quantitation of these mediators has traditionally been achieved using hyphenated mass spectrometric techniques, primarily liquid-chromatography tandem mass spectrometry. Recent advances in the field of chromatography and mass spectrometry have increased both the robustness and the sensitivity of this approach and its potential deployment for routine clinical diagnostics. In the present review, we explore the evidence supporting a role for specific SPM as potential biomarkers for patient stratification in distinct disease settings together with methodologies employed in the identification and quantitation of these autacoids.
机译:精准医学方法被广泛认为在治疗慢性炎症性疾病患者方面比目前用于管理和治疗这些患者的处方范式更有效。这是因为这种方法将考虑相关因素,包括患者根据其疾病表型对给定疗法产生反应的可能性。不幸的是,由于缺乏强大的生物标志物,特别是用于确定早期治疗反应性的生物标志物,这种精准医学范式在患者日常治疗中的应用受到极大阻碍。脂质介质在炎症发生和消退期间调节宿主免疫反应中起着核心作用。在脂质介质中,专门的促分辨介质 (SPM) 控制免疫细胞以促进炎症的消退。这些类自体是通过必需脂肪酸的立体选择性转化产生的,以产生在炎症期间动态调节的分子并发挥有效的免疫调节活性。此外,人们越来越认识到这些介质在传达几种抗炎疗法(包括他汀类药物和阿司匹林)的生物作用方面所起的作用。传统上,这些介质的鉴定和定量是通过连字符质谱技术实现的,主要是液相色谱串联质谱。色谱和质谱领域的最新进展提高了该方法的稳健性和灵敏度,并提高了其在常规临床诊断中的潜在部署。在本综述中,我们探讨了支持特定SPM作为不同疾病环境中患者分层的潜在生物标志物的证据,以及用于识别和定量这些自体的方法。

著录项

获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号